Daiwa PI Partners’ Investment in MedScope Biotech Co., Ltd. -Leading Minimally Invasive Surgery instrument producer in Taiwan- [PDF:102KB]

November 5, 2021

Daiwa PI Partners Co. Ltd

Daiwa PI Partners' Investment in MedScope Biotech Co., Ltd.

-Leading Minimally Invasive Surgery instrument producer in Taiwan-

Daiwa PI Partners Co. Ltd (President and Representative Director: Yuichi Akai, Headquarters: Gran Tokyo North Tower 1-9-1, Marunouchi, Chiyoda-ku, Tokyo; "Daiwa PI Partners") along with AXR Group, a local partner, has completed an investment in MedScope Biotech Co., Ltd (Headquarters: Taiwan; "MedScope") with the intention of a joint buyout. MedScope operates globally and specializes in the research & development, production and sales of Minimally Invasive Surgery ("MIS") instruments.

MedScope has acquired the ISO-13485 certificate and operates a GMP (Good Manufacturing

Practice) factory in Taiwan. Their main product is a disposable single-use sterile surgical instrument which provides the modern MIS a best occlusion solution.

MedScope has obtained patents in 38 countries and regions around the world, and started shipping products to Europe, the Middle East, South Africa, and India in 2020. The MIS instruments produced by MedScope is widely recognized and highly evaluated by the distributors and medical experts in each country, and sales volume is expanding each year. The demand of MIS instruments in the developed and emerging countries is increasing dramatically given the aging population as well as the development of surgery standards. This industry is expected to continue to grow in a sustainable manner.

Daiwa PI Partners will support and contribute to increase the corporate value of MedScope.

(Reference) Overview of MedScope

Headquarter	Taiwan, Miaoli County
Business	Research & Development, production, and sale of MIS instruments.
Description
Homepage	http://www.medscope.com.tw/en/index.php

Daiwa Securities Group established the SDGs Promotion Committee in 2018, incorporating the perspective of SDGs into the foundation of our management strategy, and has endeavored to provide products and services contributing to the realization of a sustainable society.

In May 2021, we formulated the management vision "Vision 2030", aiming to realize the SDGs by creating a sustainable capital cycle with the core concept of "From savings to SDGs".

The investment in MedScope is one of our ongoing efforts to contribute to the creation of a sustainable and prosperous society.

• The SDGs we aim to achieve through this investment are:
• • Goal 3: Good health and well-being
  • Goal 9: Industry, innovation and infrastructure
  • Goal 12: Responsible consumption and production

End

(Reference) Daiwa Securities Group's SDGs initiatives：

https://www.daiwa-grp.jp/english/sdgs/?cid=ad_eir_ensdgspress